OrbiMed Advisors acquires 597,729 shares of Traws Pharma at $1.67 as losses widen; stock down 61.3% YTD
OrbiMed Advisors, a 10% shareholder, purchased 597,729 shares at $1.67 on 2026-04-16, nearly doubling its stake from 605,521 to 1,203,250 shares. The transaction occurred amid a sharp deterioration: Traws reported a net loss of $-3.0M against revenue of $2.7M, and the stock has declined 61.3% from its 52-week high of $3.13. Notably, OrbiMed's cross-ticker buy track record shows 6 prior purchases with an average 90-day return of +360.7% and a 100% win rate, though this represents historical performance across multiple holdings, not predictive evidence of outcomes at Traws specifically. The purchase price of $1.67 now trades 27% below the transaction price at a current price of $1.21, reflecting continued negative momentum (30-day decline of -31.2%) since the acquisition.